Vincere Biosciences Inc. has presented new ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders, eye disorders, renal disorders, peroxisomal disorders, ataxia, pulmonary fibrosis and neurodegeneration.